5 models fit Bio-Rad Laboratories Inc. Class A Common Stock and they disagree: 0 of 5 land within 15% of the average.
Two or more of our models back this value.
Premium(i)Silver72
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, Graham number, and Dividend discount.
ACCE opinionBio-Rad Laboratories Inc. Class A Common Stock (BIO)
Fair value (5 models)
$276
ACCE price target
$340
Rating
Overvalued
Horizon
12 months
Fair value published on 14 Oct 2026, 00:00 CEST; previously $273 since 9 Oct 2026, 00:00 CEST.
ACCE price target published on 10 Oct 2026, 00:00 CEST.
Rating published on 18 Oct 2026, 15:06 CEST.
Price used: $370 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, Dividend discount, EV/EBITDA comparison, Graham number, and P/E comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
34.2% above
-25.5% to fair value
ACCE score
55
out of 100
Analysts
33% buy
3 covering
P/E
45.7x
forward 41.3x
1-year return
+9.2%
Dividend yield
0.00%
Bio-Rad Laboratories Inc. Class A Common Stock in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Bio-Rad sells life science research reagents and instruments, along with clinical diagnostics systems, including its Droplet Digital PCR platform and its Unity and Evolis-based hospital and reference lab equipment. Its edge rests on installed-base consumables: once a lab standardizes on a platform, it buys cartridges, reagents and service contracts for years, which supports the 52.0% gross margin. The near-term question is whether revenue, currently flat at -0.1% growth, stabilizes as academic and pharma research budgets recover and clinical testing volumes normalize. At a 44.8 trailing P/E and 41.3 forward, the stock prices in a recovery that the top line has not yet shown, and ROE of 3.1% leaves little margin for error. The score of 57/100 and absence from major indices suggest the name is out of favor, so the case for a deeper look depends on finding evidence that operating margin (11.2%) can expand on flat sales.
⚠ Investor warnings · 2 flagsAI-assisted·How I use AI
moderate
Revenue flat over five years
Revenue growth is -0.1% year over year and only +0.3% on a 5y CAGR, so the earnings gains rest on margins and cost control rather than top-line expansion.
moderate
Valuation stretched against model
The price trades 34.2% above the model fair value of $275.67 at a P/E of 44.7, leaving limited margin for error if growth stays near zero.
AI research notes
AI-assisted·How I use AIWritten Oct 19, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
Free cash flow over the last twelve months reached $375M, showing the business still turns sales into real cash.
Diluted share count fell 3.3% last fiscal year, so each remaining share claims a larger slice of the business.
Latest quarterly earnings per share beat expectations by 12.0%, coming in at 2.62 against 2.34 expected.
Why it could disappoint
Revenue growth was -0.1% year over year, and the five-year average is only +0.3% a year, so sales are barely expanding.
Return on equity of 3.1% is thin for a shareholder, and the stock trades at a trailing P/E of 44.7x against a sector forward median of 24.3x.
The stock trades 34.2% above the model fair value of $275.67, and only 1 of 3 analysts rate it Buy or Strong Buy.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.
Next results
Nov 4, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle
Walk me through this stock
Plain-English pros, cons, and what to watch. Pro feature.
PRO
Ask ACCE
Valuation
INVESTOR
Where BIO's valuation models land
Price
$369.95
Model fair value
$276
Model range
$113 to $456
Fair value $276
Price $370
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
Dividend discount
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.
See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.
Quality
INVESTOR
Quality and conviction INVESTOR FEATURE
The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.
+A plain reason under every score
+Conviction breakdown and growth / value / quality / momentum scores